This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Mesenchymal Stem Cell (MSC) Therapy Development
Animal mesenchymal stem cells (MSCs) are generally categorized into autologous, allogeneic, and xenogeneic MSCs in the field of cell therapy. Regardless of the type of MSC-mediated cell therapy, it demonstrates unlimited potential and room for development in treating companion animal diseases. As a pluripotent stem cell, MSCs possess the ability of self-renewal and multidirectional differentiation, can migrate to the injury site, and play an effective role in tissue repair and anti-inflammatory processes. When combined with other stem cells, it can enhance the success rate of transplantation and reduce immune rejection. BioVenic's veterinary cell therapy development team has a comprehensive understanding of the professional background of veterinary MSC-mediated therapies. By mastering key parameters, we provide high-quality one-stop solutions to researchers in the field of animal MSC therapy development.
Fig.1 The Efficacy of MSCs in the Treatment of Canine Osteoarthritis.1,2
Animal Mesenchymal Stem Cell Solution
BioVenic offers a comprehensive range of animal MSC technology services essential for cell therapy development. This includes MSC products from various species, as well as services for isolating, identifying, and genetically modifying specific MSCs. We create animal MSC media and culture systems to meet individual customer requirements. Additionally, we provide a variety of established strategies and solutions for directing stem cell differentiation to assist customers in determining cell fate.
Animal MSC Therapy Research and Development
BioVenic has a high-throughput detection platform that can efficiently analyze the therapeutic potential and functional characterization of MSCs, fully digitize their immunosuppressive function, and their ability to promote tissue and organ repair. Our specialized team also establishes a standardized technical system for screening therapeutic targets of MSCs to meet customers' scientific research needs in the field of targeted therapy.
Animal MSCs in Cell Therapy Applications
| Species | Diseases | Applications |
| Canine | Osteoarthritis | Intra-articular injection of adipose-derived stem cells (ASC) is effective in treating osteoarthritis of the elbow joint in dogs, leading to improvements in pain, lameness, range of motion, and functional ability. |
| Osteochondritis | Intra-articular injection of MSCs significantly reduces pain and improves the functional ability of affected individuals. | |
| Tendonitis and Ligaments Rupture | Autologous adipose MSCs for tendon treatment regulate the inflammatory response post-tendon repair by upregulating prostaglandin reductase 1, M2 macrophages, and proteins essential for tendon formation. This process facilitates optimal healing of scar tissue. | |
| Atopic Dermatitis | The immunomodulatory effects of MSC inhibit the activation of T cells and B cells, the release of anti-inflammatory cytokines, and reduce the proliferation of IL-4 and IFN, thereby decreasing the production of IgE. | |
| Feline | Asthma | MSCs had a positive effect on airway remodeling, reduced airway hyperresponsiveness, and decreased airway eosinophilia. |
| Kidney Disease | Intravenous injection of feline amniotic membrane-derived allogeneic MSCs resulted in a significant improvement in proteinuria, a decrease in serum creatinine levels, and a slight enhancement in urine specific gravity. | |
| Chronic Gingivostomatitis | MSCs perform immunomodulation by normalizing immune cell subsets, serum protein levels, and cytokine levels. | |
| Inflammatory Bowel Disease | MSCs have immunomodulatory and anti-inflammatory effects. After the intravenous injection of MSCs, the clinical symptoms of sick cats improved or completely disappeared. | |
| Bovine | Chronic Wound Healing | MSCs participate in clearing dead cells and necrotic tissue, promoting angiogenesis, reducing scar tissue formation, aiding in wound contraction, and stimulating epithelial regeneration, thereby promoting wound healing, and reducing local inflammation. |
| Mastitis | MSCs exhibit antimicrobial activity, enhance the expression of anti-inflammatory cytokines, antimicrobial peptides, and angiogenic genes in the milk of animals treated for mastitis, and reduce the expression of pro-inflammatory cytokines. | |
| Reproductive System Diseases | MSCs from various sources are utilized in the treatment of metritis, bilateral ovarian dystrophy, ovarian cysts, and reproductive system lesions. | |
| Diabetes Mellitus | MSCs differentiate into islet-like clusters that express insulin and glucagon. |
Why Choose Us?
BioVenic monitors the growth status and controls the variation of animal MSCs used in therapy development to ensure the reproducibility of experiments.
BioVenic utilizes high-throughput automated analysis to comprehend and characterize MSCs and their therapeutic effects or potential in specific diseases.
BioVenic has mastered a variety of strategies to enhance the survival and activity of MSCs in vitro, as well as to modify MSCs. We have developed mature technical solutions through continuous optimization and improvement.
BioVenic provides veterinary MSC therapy-related research services for clients, drawing on its extensive experience in scientific research projects related to animal mesenchymal stem cells and its profound expertise in animal stem cells. We address all scientific challenges that may arise during therapy development, ranging from basic animal MSC technology operation, gene modification, and characterization of specific disease treatment effects to high-throughput analysis. If you are interested in our services, please do not hesitate to contact us for further discussion.
References
- Image retrieved from Figure 1 "Schematic overview of mesenchymal stem cell administration in canine osteoarthritis studies [Modified from Lo Monaco et al.]", Brondeel et al., 2021, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). The original title was changed to "The Efficacy of MSCs in the Treatment of Canine Osteoarthritis."
- Brondeel, Carlien, et al. "Mesenchymal stem cell therapy in canine osteoarthritis research:"experientia docet"(experience will teach us)." Frontiers in Veterinary Science 8 (2021): 668881.